Psychosocial effects of vitiligo

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 1, 2006, Pages 1-8

  Ongenae, K ^a   Beelaert, L ^a   van Geel, N ^a   Naeyaert, Jean Marie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Coping; Management; Psychiatric; Psychosocial; Quality of life; Vitiligo

Indexed keywords

ANXIETY; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; COPING BEHAVIOR; DEPRESSION; DISEASE ACTIVITY; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DYSTHYMIA; EMOTION; ESTHETICS; HUMAN; MORBIDITY; PATIENT COUNSELING; PRIORITY JOURNAL; PSORIASIS; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; SELF ESTEEM; SLEEP DISORDER; SOCIAL CLASS; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SUICIDAL IDEATION; VITILIGO;

ADAPTATION, PSYCHOLOGICAL; BODY IMAGE; HUMANS; QUALITY OF LIFE; SELF CONCEPT; VITILIGO;

EID: 33645981285     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01369.x     Document Type: Review

References (58)

1. Porter J. The psychological effects of vitiligo: Response to impaired appearance. In: Hann SK, NordluAd JJ, eds. Vitiligo: a Monograph on the Basic and Clinical Science. Blackwell Science, Oxford, 2000: 97-100.
2. Jayaprakasam A, Darvay A, Osborne G, McGibbon D. Comparison of assessments of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002; 27: 306-308.
3. Harlow D, Poyner T, Finlay AY, Dykes PJ. Impaired quality of life of adults with skin disease in primary care. Br J Dermatol 2002; 143: 979-982.
4. Halioua B, Beumont MG, Lunel F. Quality of life in dermatology. Int J Dermatol 2000; 39: 801-806.
5. Jowett S, Ryan T. Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med 1985; 20: 425-429.
6. Finlay AY, Ryan TJ. Disability and handicap in dermatology. Int J Dermatol 1996; 35: 305-311.
7. Shuster S, Fisher GH, Harris E, Binnell D. The effect of skin disease on self image. Br J Dermatol 1987; 99 S16: 18-19.
8. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence form myth. Psychother Psychosom 2001; 70: 118-136.
9. Njoo MD, Westerhof W. Vitiligo pathogenesis and treatment. Am J Clin Dermatol 2001; 2: 167-181.
10. Finlay AY. Quality of life assessments in dermatology. Sem Cut Med Surg 1998; 17: 291-296.
11. Finlay AY. Quality of life measurement in dermatology: A practical guide. Br J Dermatol 1997; 136: 305-314.
12. McKenna KE, Stern RS. The outcome movement and new measures of severity of psoriasis. J Am Acad Dermatol 1996; 34: 534-538.
13. Porter JR, Beuf AH, Nordlund JJ, Lerner AB. Personal responses to vitiligo. Arch Dermatol 1978; 114: 1348-1385.
14. Porter JR, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders. A study of patients with vitiligo. Gen Hosp Psychiatry 1979; 1: 73-77.
15. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. Response to cosmetic disfigurement: Patients with vitiligo. Cutis 1987; 39: 493-494.
16. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol 1990; 22: 221-222.
17. Porter JR, Beuf AH, Lerner AB, Nordlund JJ. Psychosocial effect of vitiligo: A comparison of vitiligo patients with normal subjects, with psoriasis patients, and with patients with other pigmentary disorders. J Am Acad Dermatol 1986; 15: 220-224.
18. Finlay AY, Khan GK. Dermatology life quality index (DLQI) -a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
19. Kent G, Al'Abadie M. Psychologic effects of vitiligo: A critical incident analysis. J Am Acad Dermatol 1996; 35: 895-898.
20. Kent G, Al' Abadie M. Factors affecting responses on dermatology life quality index items among vitiligo sufferers. Clin Exp Dermatol 1996; 21: 330-333.
21. Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: A preliminary investigation into the effects of cognitive-behaviour therapy. Br J Med Psychol 1999; 72:385 -396.
22. Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003; 148: 363-384.
23. Ongenae K, van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol 2005; 152: 1165-1172.
24. Zghal A, Zeglaoui F, Kallel L et al. Quality of life in dermatology: Tunisian version of the skindex-29. Tunis Med 2003; 81: 34-37.
25. Rumpf HJ, Löntz W, Uesseler S. A self-administered version of a brief measure of suffering: First aspects of validity. Psychother Psychosom 2004; 73: 53-56.
26. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: Epidemiology and management. Am J Clin Dermatol 2003; 4: 833-842.
27. Picardi A, Abeni D, Melchi CF, Puddu P, Pasquini P. Psychiatric morbidity in dermatological outpatients: An issue to be recognized. Br J Dermatol 2000; 143: 983-991.
28. Thompson AR, Kent G, Smith JA. Living with vitiligo: Dealing with difference. Br J Health Psychol 2002; 7: 213-225.
29. Porter JR, Beuf AH. The effect of a racially consonant medical context on adjustment of African-American Patients to physical disability. Med Anthropol 1994; 16: 1-6.
30. Porter JR, Beuf AH. Racial variation in response to physical stigma: A study of degree of disturbance by vitiligo among black and white patients. J Health Soc Behav 1991; 32: 192-204.
31. Parsad D, Dogra S, Kanwar AJ. Quality of life in patients with vitiligo. Health Qual Life Outcomes 2003; 1: 58.
32. Sharma N, Koranne RV, Singh RK. Psychiatric morbidity in psoriasis and vitiligo: A comparative study. J Dermatol 2001; 28: 419-423.
33. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo: Prevalence and correlates in India. JEADV 2002; 16: 573-578.
34. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: A comparative study from India. J Dermatol 2001; 28: 424-432.
35. Renzi C, Picardi A, Abeni D et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002; 138: 337-342.
36. Ongenae K, van Geel N, De Schepper S, Vander Haeghen Y, Naeyaert JM. Management of vitiligo patients and attitude of dermatologists towards vitiligo. Eur J Dermatol 2004; 14: 177-181.
37. Njoo MD, Bossuyt PMM, Westerhof W. Management of vitiligo. Results of a questionnaire among dermatologists in the Netherlands. Int J Dermatol 1999; 38: 866-872.
38. Picardi A, Abeni D. Can cognitive-behavioral therapy help patients with vitiligo? Arch Dermatol 2001; 137: 786-788.
39. Agarwal G. Vitiligo: An underestimated problem. Fam Pract 1997; 15: S19-S23.
40. Grimes PE, Kenney JA. Should vitiligo be treated? Cutis 1983; 32: 343-346.
41. Njoo MD, Westerhof W, Bos JD, Bossuyt PMM. The development of guidelines for the treatment of vitiligo. Arch Dermatol 1999; 135: 1514-1521.
42. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000; 42: 245-253.
43. Salek MS, Finlay AY, Luscombe DK et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomised, double-blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422-430.
44. Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxinum A. Dermatol Surg 2002; 28: 495-499.
45. Boehncke WH, Ochsendorf F, Paeslack I, Kaufmann R, Zollner TM. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol 2002; 12: 577-580.
46. Holme SA, Beattie PE, Fleming CJ. Cosmetic camouflage advice improves quality of life. Br J Dermatol 2002; 147: 946-949.
47. Ongenae K, Dierckxsens L, Brochez L, van Geel N, Naeyaert JM. Quality of life and stigmatization profile in a cohort of vitiligo patients and effect of the use of camouflage. Dermatology 2005; 210: 279-285.
48. Gupta MA, Voorhees JJ. Psychosomatic dermatology. Arch Dermatol 1990; 126: 90-93.
49. Al' Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol 1994; 130: 199-203.
50. Papadopoulos L, Bor L, Legg C, Hawk JLM. Impact of life events on the onset of vitiligo in adults: A preliminary evidence for a psychological dimension in aetiology. Clin Exp Dermatol 1998; 23: 243-248.
51. Picardi A, Pasquini P, Cattaruzza MS et al. Stressful life events, social support, attachment security and alexithymia in vitiligo. A case-control study. Psychother Psychosom 2003; 72: 150-158.
52. Farber EM, Rein G, Lanigan SW. Stress and psoriasis. Psychoneuroimmunologic mechanisms. Int J Dermatol 1991; 30: 8-12.
53. O'Leary A. Stress, emotion and human immune function. Psychol Bull 1990; 108: 363-382.
54. Hautmann G, Panconesi E. Vitiligo: A psychologically influenced or influencing disease. Clin Dermatol 1997; 15: 879-890.
55. Al' Abadie MSK, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131: 160-165.
56. Katsambas AD, Schulpis KH, Antoniou C et al. Beta endorphin serum levels in patients with vitiligo. JEADV 1994; 3: 22-26.
57. Mozzanica N, Villa ML, Foppa S et al. Plasma α-melanocytes-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992; 26: 693-700.
58. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995; 190: 109-115.